StockData
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. (ABOS) stock

ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30
$0.19−0.04 (-15.51%)

Close on Nov 18, 2026Market cap $14.06MP/E –Yield –

Acumen Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Acumen Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$104.72M. For fiscal 2025 it was -$123.83M. The highest annual figure on record is -$7.91M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$123.83M–
FY2024Dec 31, 2024-$114.02M–
FY2023Dec 31, 2023-$61.14M–
FY2022Dec 31, 2022-$45.24M–
FY2021Dec 31, 2021-$19.58M–
FY2020Dec 31, 2020-$7.91M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.81M–
Q2 FY2026Jun 30, 2026-$32.56M–
Q1 FY2026Mar 31, 2026-$21.15M–
Q4 FY2025Dec 31, 2025-$25.20M–
Q3 FY2025Sep 30, 2025-$26.51M–
Q2 FY2025Jun 30, 2025-$41.75M–
Q1 FY2025Mar 31, 2025-$30.37M–
Q4 FY2024Dec 31, 2024-$39.60M–
Q3 FY2024Sep 30, 2024-$32.27M–
Q2 FY2024Jun 30, 2024-$24.38M–
Q1 FY2024Mar 31, 2024-$17.77M–
Q4 FY2023Dec 31, 2023-$18.49M–
Q3 FY2023Sep 30, 2023-$16.04M–
Q2 FY2023Jun 30, 2023-$13.48M–
Q1 FY2023Mar 31, 2023-$13.14M–
Q4 FY2022Dec 31, 2022-$14.25M–
Q3 FY2022Sep 30, 2022-$11.37M–
Q2 FY2022Jun 30, 2022-$10.41M–
Q1 FY2022Mar 31, 2022-$9.21M–
Q4 FY2021Dec 31, 2021-$8.42M–
Q3 FY2021Sep 30, 2021-$3.94M–
Q2 FY2021Jun 30, 2021-$3.44M–
Q1 FY2021Mar 31, 2021-$3.79M–
Q4 FY2020Dec 31, 2020-$1.34M–
Q3 FY2020Sep 30, 2020-$2.49M–
Q2 FY2020Jun 30, 2020-$2.04M–

More Acumen Pharmaceuticals figures

See a number that looks wrong?